Aspira Women’s Health Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health
23 Outubro 2024 - 12:23PM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced it has been selected by the Advanced Research Projects
Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s
Health to address critical unmet challenges in women’s health,
champion transformative innovations, and tackle health conditions
that uniquely or disproportionately affect women. Aspira will
receive $10 million in funding over two years through the Sprint
for Women’s Health launchpad track for later-stage health
solutions.
Funding from the project will support the continued development
of Aspira’s ground-breaking multi-marker blood test to aid in the
detection of endometriosis, known by its working name EndoMDx.
Aspira will receive milestone-based payments of up to $10 million
over a 2-year period. Additionally, Aspira will work with an ARPA-H
Program Manager and the ARPA-H Investor Catalyst Hub in the design,
development and commercial launch of the non-invasive test to
identify endometriosis. The award is intended to provide access to
a team of world-class subject matter experts and advisors to help
ensure the successful completion and commercial launch of the test
before the end of the contract term.
“We are honored to be an ARPA-H Sprint for Women’s Health
awardee. The selection process was extremely competitive, with over
1,700 submissions vying for funding. I am extraordinarily proud of
our team for this achievement; we have worked tirelessly to advance
endometriosis diagnostic research for many years, and I believe our
experience was the key differentiator in the selection process,”
said Nicole Sandford, CEO of Aspira Women’s Health. “Our strong
scientific foundation, unwavering focus on operational excellence
and the successful enhancement of our commercial capabilities were
instrumental in our selection.”
Dr. Sandra Milligan, Aspira’s President, and Dr. Todd Pappas,
Vice President of Research & Development, led the project
proposal and successful presentation and will serve as the
executive leaders responsible for the ARPA-H project. Dr. Milligan
stated, “Endometriosis is a devastating, chronic gynecologic
condition that affects as many as six million women in the United
States alone. The lives of these women are impacted medically,
economically, and socially. Many experience intense pain, starting
as early as 12 years old, resulting in chronic absences from work
or school. Women with endometriosis also have an increased risk of
infertility and certain cancers. Endometriosis costs the American
economy billions of dollars in lost productivity and healthcare
expense each year.”
“Currently this condition can only be identified definitively
through laparoscopic surgery and most women remain undiagnosed for
7 to 10 years,” continued Dr. Milligan. “Many also face repeated
invasive procedures over the course of their lives. There is a
tremendous need for a non-invasive test like ours, and we are
excited to move this project forward.”
Ms. Sandford concluded, “We will be holding a virtual Investor
Day on October 29th at 3:00 pm ET to provide highlights from our
successful ARPA-H presentation and an update of our development
pipeline.”
Investors interested in registering for this event can email
investors@aspirawh.com.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of non-invasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer risk for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is comprised of
two FDA-cleared tests, Ova1® and Overa®, to assess the risk of
ovarian malignancy in patients with adnexal masses planned for
surgery.
Our in-development test pipeline will expand our ovarian cancer
portfolio and address the tremendous need for non-invasive
diagnostics for endometriosis, a debilitating disease that impacts
millions of women worldwide. In ovarian cancer, we intend to
combine microRNA and protein biomarkers with patient data to
further enhance the sensitivity and specificity of our current
tests. In endometriosis, we have developed the first-ever
non-invasive test designed to identify endometriomas, one of the
most commonly occurring forms of severe endometriosis. Through our
ongoing endometriosis development program, we are combining
microRNA and protein biomarkers with patient data, with the intent
of identifying all endometriosis independent of disease location or
severity.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve a number of risks and uncertainties. Such
forward-looking statements include statements regarding, among
other things, the timing and completion of any products in the
pipeline development and other statements that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “Risk Factors”
in our most recent Annual Report on Form 10-K, for the fiscal year
ended December 31, 2023, and subsequent Quarterly Reports on Form
10-Q. If any of these risks materialize or our assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. There may be
additional risks that Aspira presently does not know, or that
Aspira currently believes are immaterial, that could also cause
actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Subsequent events
and developments may cause the Company’s assessments to change.
However, while Aspira may elect to update these forward-looking
statements at some point in the future, Aspira expressly disclaims
any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as
representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact: Jamie
SullivanDirector of Corporate
CommunicationsInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Out 2024 até Out 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024